DrugNov 29, 2023
Exela Pharma Sciences Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL (1mg/mL) recall — FDA D-0117-2024
Presence of Particulate Matter: Silicone
Class IFDA: OngoingExela Pharma Sciences LLC
10,685drug recall records
953FDA Class I records
8firms with 5+ records
Aidapak Services, LLC537 records
Database records
Records — page 48
10,685 detailed records are currently available in this category.
DrugNov 22, 2023
Omega & Delta Co Equate Hand Sanitizer (Ethyl Alcohol 62%), 7.5 FL.OZ. (221 mL) UPC 6 81131 recall — FDA D-0105-2024
Sub Potent and Super Potent Product: During an impact assessment of the DOP Hand Sanitizer product, it was identified that several lots distributed did not comply with the finished good…
Class IIFDA: OngoingOmega & Delta Co., Inc.
DrugNov 22, 2023
Omega & Delta Co DOP Instant Hand Sanitizer (Ethyl Alcohol 65%) with Moisturizers, 8FL OZ recall — FDA D-0104-2024
Sub Potent and Super Potent Product: During an impact assessment of the DOP Hand Sanitizer product, it was identified that several lots distributed did not comply with the finished good…
Class IIFDA: OngoingOmega & Delta Co., Inc.
DrugNov 22, 2023
Omega & Delta Co DOP Instant Hand Sanitizer (Ethyl Alcohol 65%) with Moisturizers, Original recall — FDA D-0103-2024
Sub Potent and Super Potent Product: During an impact assessment of the DOP Hand Sanitizer product, it was identified that several lots distributed did not comply with the finished good…
Class IIFDA: OngoingOmega & Delta Co., Inc.
DrugNov 15, 2023
Oxybutynin Chloride Extended-Release Tablet USP, 5 mg, 100 count bottles recall — FDA D-0096-2024
Failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.
Class IIFDA: CompletedZydus Pharmaceuticals (USA) Inc.
DrugNov 15, 2023
LIDOCAINE HYDROCHLORIDE 2% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass ABBOJECT recall — FDA D-0102-2024
Presence of Particulate Matter: identified as glass.
Class IFDA: TerminatedPfizer Inc.
DrugNov 15, 2023
Oxybutynin Chloride Extended-Release Tablet USP, 15 mg, 100 count bottles recall — FDA D-0098-2024
Failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.
Class IIFDA: CompletedZydus Pharmaceuticals (USA) Inc.
DrugNov 15, 2023
Pfizer 4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5mEq/mL), Glass ABBOJECT Unit recall — FDA D-0100-2024
Presence of Particulate Matter: identified as glass.
Class IFDA: TerminatedPfizer Inc.
DrugNov 15, 2023
Grato Holdings V-FORCE Homeopathic, 1 FL OZ (30 ml) per glass bottle recall — FDA D-0099-2024
Incorrect Product Formulation: product contains Active Ingredient Glandula Suprarenalis Suis 8X instead of Glandula Suprarenalis Bovine 8X (as stated on the product label).
Class IIIFDA: TerminatedGrato Holdings, Inc.
DrugNov 15, 2023
Hydrocortisone 1% and Acetic Acid 2% Otic Solution USP, 10ml dropper bottle recall — FDA D-0089-2024
Failed Impurities/Degradation Specifications:Out-of-Specification result for Hydrocortisone related impurity and slightly lower than the established level of the Hydrocortisone Assay…
Class IIIFDA: TerminatedTaro Pharmaceuticals Inc.
DrugNov 15, 2023
Montelukast Sodium Tablets, USP 10 mg recall — FDA D-0086-2024
Presence of Foreign Tablet(s)/Capsule(s): A foreign tablet was found in a bottle of Montelukast Sodium Tablets, USP 10mg, identified as metoprolol 25 mg.
Class IIFDA: TerminatedDr. Reddy's Laboratories, Inc.
DrugNov 15, 2023
Oxybutynin Chloride Extended-Release Tablet USP, 10 mg, 100 count bottles recall — FDA D-0097-2024
Failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.
Class IIFDA: CompletedZydus Pharmaceuticals (USA) Inc.
DrugNov 15, 2023
SYNTHROID recall — FDA D-0088-2024
Labeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose.
Class IIIFDA: OngoingAbbVie Inc.
DrugNov 15, 2023
REMEDY ANTIFUNGAL Clinical TREAT Antifungal Powder, Vanilla Scent, 3 OZ (85 g) tube, Active recall — FDA D-0091-2024
CGMP deviations: the product was shipped from the Manufacturer to a Medline warehouse and released to stock while it was still under investigation for low assay results on the active…
Class IIFDA: TerminatedMEDLINE INDUSTRIES, LP - Northfield
DrugNov 15, 2023
Ranolazine Extended-Release Tablets 500mg, 60 Tablets per bottle recall — FDA D-0092-2024
Failed Dissolution Specifications: Out of specification for dissolution.
Class IIFDA: OngoingGlenmark Pharmaceuticals Inc., USA
DrugNov 15, 2023
LIDOCAINE HYDROCHLORIDE 1% Lidocaine HCl Injection, USP, 50mg/5mL(10mg/mL), Glass ABBOJECT recall — FDA D-0101-2024
Presence of Particulate Matter: identified as glass.
Class IFDA: TerminatedPfizer Inc.
DrugNov 8, 2023
GlaxoSmithKline Consumer Healthcare Holdings TUMS Antacid, Calcium Carbonate USP 1000 mg recall — FDA D-0076-2024
Presence of Foreign Substance: The foreign material is primarily comprised of glass mineral wool.
Class IIFDA: CompletedGlaxoSmithKline Consumer Healthcare Holdings LLC
DrugNov 8, 2023
TUMS Antacid, Calcium Carbonate USP 1000 mg, Peppermint flavor, chewable tablets, 72-count recall — FDA D-0073-2024
Presence of Foreign Substance: The foreign material is primarily comprised of glass mineral wool.
Class IIFDA: CompletedGlaxoSmithKline Consumer Healthcare Holdings LLC
DrugNov 8, 2023
TUMS Antacid, Calcium Carbonate USP 1000 mg, Assorted Berries flavor, chewable tablets recall — FDA D-0079-2024
Presence of Foreign Substance: The foreign material is primarily comprised of glass mineral wool.
Class IIFDA: CompletedGlaxoSmithKline Consumer Healthcare Holdings LLC
DrugNov 8, 2023
TUMS Antacid, Calcium Carbonate USP 1000 mg, Peppermint flavor, chewable tablets recall — FDA D-0074-2024
Presence of Foreign Substance: The foreign material is primarily comprised of glass mineral wool.
Class IIFDA: CompletedGlaxoSmithKline Consumer Healthcare Holdings LLC
DrugNov 8, 2023
GYNAZOLE 1 Gynazole-1, (Butoconazole Nitrate) Vaginal Cream USP, 2%, Net Wt 5.8 g per recall — FDA D-0081-2024
Incorrect Product Formulation: Hydrophilic Colloidal Silica was used to manufacture the product rather than Hydrophobic Colloidal Silica as required by the manufacturing process.
Class IIFDA: OngoingPadagis US LLC
DrugNov 8, 2023
Liothyronine Sodium Tablets, USP, 5 mcg, 100-count bottles recall — FDA D-0083-2024
Failed Impurities/Degradation Specifications.
Class IIFDA: TerminatedSUN PHARMACEUTICAL INDUSTRIES Inc.
DrugNov 8, 2023
Strong Iodine Solution U.S.P. (Lugol's Solution) (Iodine 5%), 14 mL Glass Dropper bottle in recall — FDA D-0082-2024
CGMP Deviations: Recall due to the absence of USP CGMP compendial requirements.
Class IIFDA: TerminatedSafecor Health, LLC
DrugNov 8, 2023
Liothyronine Sodium Tablets, USP, 25 mcg, 100-count bottles recall — FDA D-0084-2024
Failed Impurities/Degradation Specifications.
Class IIFDA: TerminatedSUN PHARMACEUTICAL INDUSTRIES Inc.
How to use this drug recall index
A drug recall record can include the reason for recall, firm, status, distribution pattern, quantity and FDA classification. This site does not provide medical advice; it organizes public recall information and links users back to official sources.
Recall Lookup USA keeps the last complete source record available when an official data service is temporarily unavailable. When a source provides only a few fields, we show only those known facts rather than padding the page with generic text.
What the database can and cannot tell you
This database is designed for discovery and reference. It can help you locate a relevant recall record, identify the recalling firm or NHTSA campaign, compare dates and classifications, and follow the official source. It is not a substitute for a VIN-specific NHTSA check, a manufacturer notice, medical advice or instructions issued by the recalling company.